Cargando…

Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series

BACKGROUND: The classic phenotype of CLN2 disease (neuronal ceroid lipofuscinosis type 2) typically manifests between ages 2 and 4 years with a predictable clinical course marked by epilepsy, language developmental delay, and rapid psychomotor decline. Atypical phenotypes exhibit variable time of on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wibbeler, Eva, Wang, Raymond, Reyes, Emily de los, Specchio, Nicola, Gissen, Paul, Guelbert, Norberto, Nickel, Miriam, Schwering, Christoph, Lehwald, Lenora, Trivisano, Marina, Lee, Laura, Amato, Gianni, Cohen-Pfeffer, Jessica, Shediac, Renée, Leal-Pardinas, Fernanda, Schulz, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027928/ https://www.ncbi.nlm.nih.gov/pubmed/33356800 http://dx.doi.org/10.1177/0883073820977997

Ejemplares similares

Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration
por: Kim, Aryun, et al.
Publicado: (2020)

Impact of the COVID-19 pandemic on access to the cerliponase alfa managed access agreement in England for CLN2 treatment
por: Mortensen, Amanda, et al.
Publicado: (2022)

Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2)
por: Gissen, Paul, et al.
Publicado: (2021)

Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease
por: Hammon, Kevin, et al.
Publicado: (2021)

Cerliponase alfa for neuronal ceroid lipofuscinosis type 2 disease
Publicado: (2019)

Visual perception and macular integrity in non-classical CLN2 disease
por: Atiskova, Yevgeniya, et al.
Publicado: (2022)

Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy
por: Specchio, Nicola, et al.
Publicado: (2020)

Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa
por: Schaefers, J., et al.
Publicado: (2021)

Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients
por: Mole, Sara E., et al.
Publicado: (2021)

Language Delay in Patients with CLN2 Disease: Could It Support Earlier Diagnosis?
por: Nickel, Miriam, et al.
Publicado: (2023)

“Real world effectiveness of cerliponase alfa in classical and atypical patients. A case series”
por: Espitia Segura, O.M., et al.
Publicado: (2021)

Development of the “Hamburg Best Practice Guidelines for ICV−Enzyme Replacement therapy (ERT) in CLN2 Disease” Based on 6 Years Treatment Experience in 48 Patients
por: Schwering, Christoph, et al.
Publicado: (2021)

An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy
por: Thompson, Dorothy A., et al.
Publicado: (2021)

Natural History Studies in NCL and Their Expanding Role in Drug Development: Experiences From CLN2 Disease and Relevance for Clinical Trials
por: Nickel, Miriam, et al.
Publicado: (2022)

Correction: An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy
por: Thompson, Dorothy A., et al.
Publicado: (2021)

Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype
por: Soldati, Chiara, et al.
Publicado: (2021)

Data on characterizing the gene expression patterns of neuronal ceroid lipofuscinosis genes: CLN1, CLN2, CLN3, CLN5 and their association to interneuron and neurotransmission markers: Parvalbumin and Somatostatin
por: Minye, Helena M., et al.
Publicado: (2016)

A comparative study of the degradation of yeast cyclins Cln1 and Cln2
por: Quilis, Inma, et al.
Publicado: (2016)

Epileptic Encephalopathy
por: Specchio, Nicola, et al.
Publicado: (2012)

Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome
por: Hendriksz, Christian J., et al.
Publicado: (2016)

Electroretinography data from ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinoses
por: Russell, Katharina N., et al.
Publicado: (2021)

in vivo localization of the neuronal ceroid lipofuscinosis proteins, CLN3 and CLN7, at endogenous expression levels
por: Mohammed, Alamin, et al.
Publicado: (2017)

Natural history of retinal degeneration in ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinoses
por: Murray, S. J., et al.
Publicado: (2022)

Phenotypic variant of CLN3 mutation
por: Honasoge, Avinash, et al.
Publicado: (2022)

Progressive MRI brain volume changes in ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinosis
por: Murray, Samantha J, et al.
Publicado: (2023)

Glycerophosphoinositol is Elevated in Blood Samples From CLN3(Δex7-8) pigs, Cln3(Δex7-8) Mice, and CLN3-Affected Individuals
por: Brudvig, Jon J, et al.
Publicado: (2022)

Autophagic vacuolar myopathy is a common feature of CLN3 disease
por: Radke, Josefine, et al.
Publicado: (2018)

Loss of Cln3 Function in the Social Amoeba Dictyostelium discoideum Causes Pleiotropic Effects That Are Rescued by Human CLN3
por: Huber, Robert J., et al.
Publicado: (2014)

Timing of cognitive decline in CLN3 disease
por: Kuper, Willemijn F. E., et al.
Publicado: (2018)

A tailored Cln3(Q352X) mouse model for testing therapeutic interventions in CLN3 Batten disease
por: Langin, Logan, et al.
Publicado: (2020)

Modeling PCDH19-CE: From 2D Stem Cell Model to 3D Brain Organoids
por: Borghi, Rossella, et al.
Publicado: (2022)

Association between CLN3 (Neuronal Ceroid Lipofuscinosis, CLN3 Type) Gene Expression and Clinical Characteristics of Breast Cancer Patients
por: Makoukji, Joelle, et al.
Publicado: (2015)

Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment
por: Iwan, Katharina, et al.
Publicado: (2022)

FRET-Assisted Determination of CLN3 Membrane Topology
por: Ratajczak, Ewa, et al.
Publicado: (2014)

Role of Cln1 during melanization of Cryptococcus neoformans
por: García-Rodas, Rocío, et al.
Publicado: (2015)

CLN8 disease caused by large genomic deletions
por: Beesley, Clare, et al.
Publicado: (2016)

Exogenous Flupirtine as Potential Treatment for CLN3 Disease
por: Maalouf, Katia, et al.
Publicado: (2020)

The CLN3 gene and protein: What we know
por: Mirza, Myriam, et al.
Publicado: (2019)

PB2314: OLIPUDASE ALFA FOR ADULTS WITH ACID SPHINGOMYELINASE DEFICIENCY: IMPROVEMENTS IN CROSSOVER PLACEBO PATIENTS AND FURTHER IMPROVEMENTS IN ORIGINAL OLIPUDASE ALFA PATIENTS AFTER 2 YEARS IN ASCEND TRIAL
por: Villarrubia, J., et al.
Publicado: (2022)

Long-term safety and dose escalation of intracerebroventricular CLN5 gene therapy in sheep supports clinical translation for CLN5 Batten disease
por: Mitchell, Nadia L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5n04ugikve665lc6dhi7f60jqr